With a host of factors to consider in cell and gene manufacture, upscaling is still no small task. However, as industry experience accumulates and new technologies arrive on the market, there are an increasing number of options for developers looking to get their therapeutic on the road to the clinic.

ERVs have been strongly associated with overall survival in cancer patients. Evaxion hopes they can act as therapeutic targets for non-responsive immunotherapy patients.

Insights on antigen-specific immunotherapy and the immunomodulatory functions of therapeutic chaperones at Immuno UK 2022.

Thanks to the FDA's new AI-powered imaging tool, the safety profile of newly developed biosimilar therapeutic protiens may improve.